Risks, costs, and alternatives to platelet transfusions. - Wikidata - awgldk - TriplyDB

Risks, costs, and alternatives to platelet transfusions.

Risks, costs, and alternatives to platelet transfusions.

http://www.wikidata.org/entity/Q33328995

about

Metalloproteinase regulation improves in vitro generation of efficacious platelets from mouse embryonic stem cells Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors.Hematology in palliative medicine.Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells Covalently immobilized glycosaminoglycans enhance megakaryocyte progenitor expansion and platelet release Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy.Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.

P2860

Q30483213-CAE2CB29-7934-4483-8AAB-31CA7CE978BD Q33336625-A6747C57-E9C5-4E44-BD08-9E39E6185E42 Q33346849-05FAA606-11C3-497B-A56C-9AA78EE32263 Q33364223-FC73736F-58E0-40C6-9C3C-B61FFFF3FAE0 Q33392928-6B08D447-2F47-4CAB-B78C-598F1C1F6470 Q33393835-63C7E6EB-8D53-4988-B8D6-B43887118BE4 Q33397918-1F4231CC-E5C2-4A2B-8BDE-0B5C01E11CFC Q33431466-976D99B5-757E-4689-8FEC-5EC8BFE620DE

P2860

Risks, costs, and alternatives to platelet transfusions.

http://www.wikidata.org/entity/Q33328995

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Risks, costs, and alternatives to platelet transfusions.

@ast

Risks, costs, and alternatives to platelet transfusions.

@en

Risks, costs, and alternatives to platelet transfusions.

@nl

type

label

Risks, costs, and alternatives to platelet transfusions.

@ast

Risks, costs, and alternatives to platelet transfusions.

@en

Risks, costs, and alternatives to platelet transfusions.

@nl

prefLabel

Risks, costs, and alternatives to platelet transfusions.

@ast

Risks, costs, and alternatives to platelet transfusions.

@en

Risks, costs, and alternatives to platelet transfusions.

@nl

P1433

Q33328995-462BA88A-42C1-4BE6-AB50-84E920E68DBD

P1476

Q33328995-7C522519-92EB-48DE-9B26-183189F2B1D2

P2093

Q33328995-8B7C33E6-15FE-4083-99BE-25EC06168D24

Q33328995-A227991A-F5B1-4575-9F88-0AB18DBA78EF

P2860

Q33328995-062AE9D8-92AA-4BC2-A6F0-BEDE2EB926C8

Q33328995-0902D602-47C9-49C7-873F-EE1B6ED0A967

Q33328995-0DEC1278-0498-4D98-8246-BF4E350E1B1B

Q33328995-1B05F5FA-50B4-4A7B-BA39-2CB51F116B81

Q33328995-1C31924A-0290-48A6-830E-DBD7E4C61496

Q33328995-1FC020E3-5040-4237-8EFD-5D8FC49A2426

Q33328995-27C89E52-CA05-4B9C-BDFB-7A0407BC4931

Q33328995-3ABD5ECB-4555-4696-8B8D-3D186771BE0F

Q33328995-3AEAE2A2-0B41-4E7B-8831-E111AC4F6CEB

Q33328995-3F544EB4-5E7A-44C0-AF26-5499777F060D

P304

Q33328995-73126D53-5404-43DD-8421-B5283B69EECB

P31

Q33328995-DA8C825B-652C-4743-8E69-7129ABF77631

P356

Q33328995-389E8428-0491-4B49-BCB8-5E3064A4C33E

P433

Q33328995-B5076BFF-9DE3-4291-9A5D-FFDB10A1F60F

P478

Q33328995-28A6B0FD-F83B-4CA7-A29A-AD617FC3FCCE

P577

Q33328995-EEB8F186-F2A4-44F5-9981-E5133FC51EA0

P698

Q33328995-DCAD6A94-5D16-455C-9609-DDAFE2E23CE9

P356

10428199909083382

P1433

Leukemia & Lymphoma

P1476

Risks, costs, and alternatives to platelet transfusions.

@en

P2093

Anderson KC

http://www.w3.org/2001/XMLSchema#string

Webb IJ

http://www.w3.org/2001/XMLSchema#string

P2860

The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin

Selection of platelets for refractory patients by HLA matching and prospective crossmatching.

A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters.

Controversies in transfusion medicine. Prophylactic platelet transfusion therapy: pro.

Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.

Septic reactions to platelet transfusions. A persistent problem.

Selection of unrelated compatible platelet donors by lymphocyte HL-A matching.

Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia.

The role of the plasma from platelet concentrates in transfusion reactions.

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.

P304

71-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428199909083382

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

1999-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10350334

http://www.w3.org/2001/XMLSchema#string